Drugs / 18F-DA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03541720 | Apr 2019 → Jan 2027 expected | neuroblastoma, pheochromocytoma | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-DA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03541720 ↗ |
| Known as | 18F-fluorodopamine | “18F-DA (18F-fluorodopamine) has been shown to be safe and more effective than 123I-mIBG in analyzing the tumor pheochromocytoma, which is closely related to neuroblastoma.” NCT03541720 ↗ |
| Modality | Diagnostic / imaging agent | “18F-DA is an investigational PET radiotracer” NCT03541720 ↗ |
| Route | Intravenous | “Patients receive an intravenous injection of a small (tracer) dose of 18F-DA.” NCT03541720 ↗ |